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The pro-tumoral function of HACE1
Najla El-Hachem and Robert Ballotti
HACE1 (HECT Domain and Ankyrin Repeat 
Containing E3 Ubiquitin Protein Ligase 1) is an E3 
ubiquitin ligase composed of six N-terminal ankyrin 
repeats linked to a C-terminal HECT domain [1]. Ankyrin 
repeats allows substrate recognition, whereas the HECT 
domain is essential for ubiquitinylation. HACE1 is 
ubiquitously expressed in all normal human tissues, 
with elevated expression in the heart, brain, kidney 
and pancreas. It is mainly located in the endoplasmic 
reticulum, the Golgi [2] and the cytoplasm. Initially, 
the analysis of chromosome translocation in Wilms’ 
tumors identified HACE1 as a tumor suppressor [1], 
and similar observations were made in other neoplasms, 
such as breast cancer, hepatocellular carcinoma, B and 
NK cell lymphomas. A HACE1 knock-out mouse model 
[3] also supported a tumor suppressor role for HACE1, 
however, tumors mainly developed in animals that had 
lost p53, another tumor suppressor. HACE1 expression is 
frequently downregulated in cancers due to chromosomic 
rearrangements or DNA methylation at the HACE1 locus, 
which offers further evidence for its tumor suppressor 
activity. Furthermore, HACE1 was found to be mutated 
in cancer tissues and these mutations appeared to dampen 
its tumor suppressor activity [4]. Parallel studies focusing 
on the mechanism of RAC1 degradation showed that 
HACE1 promoted poly-ubiquitination of GTP-RAC1 in 
K48, allowing its proteasomal degradation. Thus, HACE1 
is a key player in the control of active RAC1 levels [5]. 
Given the extensive and compelling data demonstrating 
the pro-oncogenic function of RAC1, the role of HACE1 
in the degradation of RAC1 is consistent with its tumor 
suppressor activity.
In melanoma, the RAC1 P29S mutation is one of 
the most common somatic mutations after BRAFV600 and 
NRASQ61. In contrast to the BRAF or NRAS mutations, 
the RAC1 mutation displays a signature of ultraviolet B 
radiation (C→T substitutions at dipyrimidine sites), which 
is the main etiological factor for melanoma. The P29S 
mutation is an oncogenic mutation that maintains RAC1 in 
a GTP-bound form and increases melanocyte proliferation 
and migration [6].
Therefore, we reasoned that HACE1, which 
controls RAC1 stability, would have a predominant 
tumor suppressor role in melanoma. Nevertheless, initial 
analysis of publicly available datasets showed that 
HACE1 expression was maintained in melanoma, at levels 
comparable to normal melanocytes or nevi, and HACE1 
expression was even higher in patients with poor survival 
(GSE19234). Further, using multiple melanoma cell lines 
or short-term melanoma cell cultures, we demonstrated 
that HACE1 silencing inhibited melanoma cell adhesion 
and migration in vitro. Similarly, lung colonization was 
dramatically impaired in HACE1-deficient melanoma 
cells, while HACE1 over-expression increased the 
capacity of the poorly metastatic 501MEL cells to 
colonize the lungs. Taken together, these observations 
support a pro-tumorigenic role of HACE1 in melanoma. 
This unexpected result prompted us to investigate the 
molecular mechanisms that could explain the role of 
HACE1 in melanoma.
Transcriptomic analyses demonstrated that HACE1 
silencing induced a modification in the gene expression 
profile characterized by the inhibition of a set of genes 
involved in cell movement, migration and invasion, 
including ITGAV, ITGB1, PLAU and SDC4. These genes 
are regulated by fibronectin but we did not observe any 
down-regulation of FN1 upon HACE1 silencing. However, 
we demonstrated that HACE1 inhibition decreased 
fibronectin secretion and identified fibronectin as a new 
HACE1 substrate. Interestingly, HACE1 does not promote 
the degradative K48 ubiquitination of fibronectin, rather, 
it induces K27 ubiquitination that controls fibronectin 
secretion. Similarly, HACE1 has been reported to control 
YB1 secretion through K27 ubiquitination [7].
Fibronectin needs to be secreted before it can 
interact with its receptors (integrins), and consequently 
activate downstream signalling pathways and regulate 
specific transcriptomic programs, including ITGAV and 
ITGB1 expression. Therefore, by controlling fibronectin 
secretion, HACE1 is a key player in the regulation of a 
feed-forward loop between integrins and fibronectin that 
plays a key role in adhesion, migration and metastatic 
ability of melanoma cells.
Our data do not agree with the existing dogma that 
attributes a universal tumor suppressor and point out the 
existence of specific functions of HACE1 according to 
the cellular context. This hypothesis is strengthened by 
analysis of TCGA data sets, which show that HACE1 
behaves as a tumor suppressor (individuals with the 
highest 20% of HACE1 expression have increased 
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survival) in acute myeloid leukemia and in head and 
neck squamous carcinoma, while it has a pro-oncogenic 
function (individuals with the highest 20% of HACE1 
expression have decreased survival) in sarcoma and 
uterine corpus endometrial carcinoma. 
These apparent contradictory roles of HACE1 
can be understood in light of its complex molecular 
functions. Indeed, HACE1 does not only target RAC1 
to the proteasome, HACE1 also interacts with RAB 1, 
4 and 11 GTPases and is involved in Golgi membrane 
fusion during the cell cycle [2], suggesting that HACE1 
loss would impair Golgi functioning and cell division. 
The HACE1 protein has also been shown to promote 
K48 ubiquitination of optineurin for its targeting to the 
autophagic degradation [8]. However, in human lung 
cancer cells the tumor suppressor function of HACE1 
appears to be very dependent on optineurin expression. 
It can be hypothesized that the interaction between 
HACE1 and optineurin is regulated by post-translational 
modifications, such as phosphorylation, which would 
consequently modulate the cellular functions of HACE1 
according to the activation of specific signaling pathways. 
Finally, HACE1 also promotes the K63 ubiquitinylation 
of the TRAF2 adapter protein that is required for TNF-
induced NFKB activation and apoptosis [9]. Again, 
HACE1 exhibits contradictory functions, as NFKB 
pathway is a known anti-apoptotic pathway. 
To summarize, HACE1 is an E3 ligase that is 
involved in the activation of antagonistic cellular 
functions, and which drives K27, K48 and K63 
ubiquitination on different substrates. Therefore, the 
role of HACE1 cannot be reduced merely to its effect on 
RAC1 degradation and the tumor suppressor function 
that has been observed in several neoplasms. Our work 
demonstrates a pro-tumoral role of HACE1 in melanoma 
cells and opens new avenues of research to decode the 
cell- or context-specific molecular cascades that orientate 
HACE1 towards a pro- or anti-tumoral role.
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